• Beatriz G Giráldez, Rafael Toledano, Irene García-Morales, Antonio Gil-Nagel, Francisco Javier López-González, Diego Tortosa, Joaquín Ojeda, and José M Serratosa.
• Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigaciones Sanitarias Fundación Jiménez Díaz and CIBERER, Avda. Reyes Católicos, 2, 28040 Madrid, Spain.
• Seizure. 2015 Jul 1; 29: 119-22.

PurposeThe goal of this study is to report the efficacy and tolerability of lacosamide (LCM) monotherapy, as first-line and conversion regimens, in the treatment of patients with partial-onset seizures.MethodsWe retrospectively reviewed the charts of patients with focal epilepsy on LCM monotherapy from six centers in Spain. Efficacy and tolerability were evaluated in the overall group and in subgroups of patients who were naive to antiepileptic drug (AED) therapy (Group 1) and those who had previously been treated with AEDs (Group 2).ResultsSixty-six patients were identified including 18 patients in Group 1 and 48 patients in Group 2. Patients were followed up for 0.5-54 months in monotherapy (mean 15.5 months). Forty-two (63.6%) patients remained seizure-free during all the follow-up. At 6 and 12 months, seizure-free rates were 77.6% and 72.3%, respectively. The drug was withdrawn in 10 (15%) patients (3 side effects, 6 lack of efficacy, 1 other reason). Fifteen (22.7%) patients reported mild to moderate side effects with the use of LCM. No differences were found between Groups 1 and 2 regarding efficacy outcomes or tolerability issues.ConclusionsIn our series more than two-thirds of the patients remained seizure-free on LCM monotherapy. Side effects were generally mild and led to discontinuation in only 3/66 (4.5%) patients. Our experience suggests that LCM monotherapy, either as first-line or after conversion, may be a valuable option for patients with focal epilepsy.Copyright © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

29 keywords...

hide…